Efficacy and Safety of Pregabalin/Tramadol Combination Versus Pregabalin in Acute Pain of Neuropathic Origin (LOBUXALIII)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05324059|
Recruitment Status : Not yet recruiting
First Posted : April 12, 2022
Last Update Posted : April 20, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Neuropathic Pain||Drug: Pregabalin 75mg/ Tramadol 50 mg Drug: Pregabalin 75mg||Phase 3|
Study to evaluate the efficacy and safety of the fixed-dose combination of Pregabalin/Tramadol versus Pregabalin in the management of acute pain of neuropathic origin. Patients who meet the inclusion criteria of the protocol and start treatment with the combination Pregabalin / Tramadol (75 mg / 50 mg) or Pregabalin 75 mg will be included. To evaluate the proportion of subjects who reported a success rate in the reduction of pain by 50%, the percentage of change in the pain intensity reported through the Visual Analog Pain Scale (VAS) will be calculated. This percentage will be categorized and the proportion of patients per treatment group will quantify. Changes in pain intensity during the intervention will be evaluated with the fixed-dose combination of Pregabalin/Tramadol (75 mg / 50 mg) or Pregabalin 75 mg, comparing the average difference in pain reported through VAS at days 1, 3, 5, 7, 10, 13 and 15 with respect to their baseline measurement. The mean change in reported neuropathic pain intensity across the DN4 questionnaire will also be evaluated, comparing its measurement on day 3, 10 and 15 with respect to the baseline, in each treatment group.
At visit 1 (day 3) the need for dose escalation will be evaluated (Pregabalin/Tramadol (150 mg / 50 mg) or pregabalin (150 mg)) in both treatment groups, continuing with its follow-up in the evaluation of the intensity of pain reported by EVA and DN4. The proportion of subjects who started on the dose of Pregabalin / Tramadol (75 mg / 50 mg) or Pregabalin 75 mg, those that required adjustment of dose to treatment (Pregabalin / Tramadol (150 mg / 50 mg) or Pregabalin (75 mg)), as well as the proportion of patients who suspended the treatment.
The percentage of adherence to the intervention by treatment group will be reported.
The proportion of adverse events presented during the conduct of the study will be evaluated, regardless of the dose administered, to all the subjects who have received at least one dose of the investigational drug Which will be reported be reported through frequencies and percentages and classified according to frequency, gravity, severity (intensity) and the causality of the clinical manifestation.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||110 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Confirmatory Study of Efficacy and Safety of the Pregabalin/Tramadol Combination Versus Pregabalin in the Management of Acute Pain of Neuropathic Origin.|
|Estimated Study Start Date :||May 2022|
|Estimated Primary Completion Date :||June 2022|
|Estimated Study Completion Date :||July 2022|
Experimental: Group A: Pregabalin/Tramadol
Fixed dose combination tablet of 75 mg Pregabalin and 50 mg of Tramadol, orally, every 12 hours.
Drug: Pregabalin 75mg/ Tramadol 50 mg
Pharmaceutical Form: Tablet Dosage: 75 mg / 50 mg Administration way: oral
Other Name: LOBUXAL
Active Comparator: Group B: Pregabalin
Monotherapy with 75 mg of Pregabalin, orally, every 12 hours.
Drug: Pregabalin 75mg
Pharmaceutical Form: Capsule Dosage: 75 mg Administration way: oral
Other Name: Pregabalin
- Proportion of subjects with a success rate of >50% in pain reduction [ Time Frame: 15 days ]Evaluate the proportion of subjects who reported a success rate of >50% in pain reduction at completion of the intervention, measure by the VAS (Visual Analog Scale) per treatment group. In a straight 10 centimeter line in which one end means no pain and the other end means the worst pain imaginable, the participants mark the amount of pain feeling at that moment.
- Mean change in pain intensity by VAS (Visual Analog Scale) [ Time Frame: Baseline,1,3,5,7,10, 13 and 15 days ]Evaluate the mean change in pain intensity reported on days 1, 3, 5, 7, 10, 13, and 15 with respect to its baseline measurement, reported through the VAS (Visual Analog Scale) per treatment group. In a straight 10 centimeter line in which one end means no pain and the other end means the worst pain imaginable, the participants mark the amount of pain feeling at that moment.
- Mean change in pain intensity by DN4 questionnaire [ Time Frame: Baseline, 3, 10 and 15 days ]Evaluate the mean change in pain intensity reported on days 3, 10 and 15 with respect to its baseline measurement according to the DN4 Questionnaire by treatment group.
- Proportion of subjects requiring dose escalation [ Time Frame: Day 3 ]Evaluate the proportion of subjects who required dose escalation (from Pregabalin/Tramadol 75mg/50 to 150 mg/ 50 mg or Pregabalin 75mg to 150 mg, as appropriate) during the intervention, by treatment group.
- Frequency of adverse events [ Time Frame: 15 days ]Compare the frequency of adverse events presented during the study between the treatment groups.
- Intensity of adverse events. [ Time Frame: 15 days ]Compare the intensity of adverse events presented by treatment group.
- Adherence percentage [ Time Frame: 15 days ]Report the percentage of adherence to the intervention by treatment group, using the count of tablets returned to the research site
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Any gender.
- That the subject agrees to participate in the study and give its informed consent in writing.
- Age >18 years and ≤65 years of age at the start of the study.
- Neuropathic Pain Questionnaire (DN4) ≥ 4.
- Patients with proven tolerability (absence of moderate-serious adverse events) to pregabalin, defined by consumption of pregabalin 50 mg/day for 3 days.
- Women of childbearing age who have an acceptable method of contraception (eg barrier, oral hormonal, injectable, subdermal).
- Contraindication and known hypersensitivity to the use of pregabalin and/or tramadol.
- The patient is participating in another clinical study involving an investigational treatment or participated in any in the previous 4 weeks.
- In the medical opinion, a disease that affects the prognosis and prevents outpatient management, for example, but not limited or restricted to: terminal cancer, heart failure, obstruction gastrointestinal including paralytic ileus, suspected surgical abdomen, respiratory failure with scheduled surgical or hospital procedures.
- Positive pregnancy test, women who are pregnant, nursing or planning a pregnancy during the conduct of the study.
- Patients with a diagnosis of respiratory diseases: status asthmaticus, asthma, chronic obstructive pulmonary disease (COPD), cor pulmonale, acute respiratory depression, hypercapnia.
- Patients who are receiving monoamine oxidase inhibitors (MAOIs) or who have received within the last 2 weeks.
- Patients with a history of seizure disorders, epileptic status, and grand mal seizures.
- Patients with a history of severe depression of the central nervous system due to consumption of opiates.
- History of acute intoxications with hypnotics, opioid analgesics and psychotropics.
- History of alcohol or drug abuse (including opiates) in the last year according to DSM-V.
- Patients with a history of severe head trauma and/or brain edema.
- History/presence of any disease or condition which, in the opinion of the Investigator, could pose a risk to the patient or confound the efficacy and safety results of the study.
- Patients with symptoms suggestive of active COVID-19 infection (i.e., fever, cough, dyspnea) and/or contact in the last 14 days with a suspected or positive patient for COVID-19.
- Patients whose participation in the study may be influenced (employment relationship with the center investigator or sponsor, inmates, etc.).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05324059
|Contact: Jorge A González, PhD||5254883785 ext firstname.lastname@example.org|
|Contact: Yulia Romero-Antonio, B.S.||5554883700 ext email@example.com|
|Laboratorio Silanes, S.A. de C.V.|
|Ciudad de México, Mexico, 11000|
|Contact: Jorge A Gonzalez, PhD +5254883785 ext 3761 firstname.lastname@example.org|
|Contact: Yulia Romero-Antonio, B.S. 5554883700 ext 3779 email@example.com|
|Principal Investigator: Rodrigo Suárez Otero, M.D.|
|Principal Investigator: Isabel E Rucker, M.D.|
|Principal Investigator: Luis R Partida, M.D.|
|Principal Investigator: Alfonso Hernández Zepeda, M.D.|
|Principal Investigator: Ma. Dolores Alonso Matínez, M.D.|
|Principal Investigator:||Rodrigo Suárez Otero, M.D||Independent consultant|
|Principal Investigator:||Isabel E Rucker, M.D||Clinical Research Institute|
|Principal Investigator:||Luis R Partida, M.D||Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V.|
|Principal Investigator:||Alfonso Hernández Zepeda, M.D||IMACEN S.A. de C.V.|
|Principal Investigator:||Ma. Dolores Alonso Martínez, M.D||CICMEX, Centro de Investigación Clínica de México S. de R.L de C.V.|
|Responsible Party:||Laboratorios Silanes S.A. de C.V.|
|Other Study ID Numbers:||
|First Posted:||April 12, 2022 Key Record Dates|
|Last Update Posted:||April 20, 2022|
|Last Verified:||April 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Peripheral Nervous System Diseases
Nervous System Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Central Nervous System Depressants